

AMENDMENTS TO THE SPECIFICATION:

Please insert the following at page 6, before line 1:

BRIEF DESCRIPTION OF THE DRAWINGS

The invention will now be described in more detail with reference to the accompanying drawings, in which:

Figure 1 is an X-ray diffraction spectrum (XRD) of the crystalline form A of moxifloxacin hydrochloride;

Figure 2 is a solid state carbon-13 NMR spectrum of the crystalline form A of moxifloxacin hydrochloride;

Figure 3 is an infrared spectrum of the crystalline form A of moxifloxacin hydrochloride;

Figure 4 is a DSC trace of the crystalline form A of moxifloxacin hydrochloride;

Figure 5 is an X-ray diffraction spectrum of the crystalline form A of moxifloxacin hydrochloride after being left in air at room temperature for 5 days;

Figure 6 is an X-ray diffraction spectrum (XRD) of the crystalline form B of moxifloxacin hydrochloride;

Figure 7 is an infrared spectrum of the crystalline form B of moxifloxacin hydrochloride; and

Figure 8 is a DSC trace of the crystalline form B of moxifloxacin hydrochloride.